RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.

Bloodstream Infections Clinical Trial

— MERINO  

Official title:

Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02176122
• Other study ID #: ACTRN12613000532707
• Status: Terminated
• Phase: Phase 4
• First received: June 24, 2014
• Last updated: November 22, 2017
• Start date: February 2014
• Est. completion date: August 7, 2017

Study information

• Verified date: November 2017
• Source: The University of Queensland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

No randomized controlled trials (RCTs) have yet been performed comparing different treatment options for AmpC or ESBL-producing Enterobacteriaceae. During the last 10 years we have seen an exponentially increasing rate of carbapenem resistance worldwide, including Australia and New Zealand. The investigators urgently need data from well-designed RCTs to guide clinicians in the treatment of antibiotic resistant Gram-negative infections. The investigators face a situation where a commonly used antibiotic for these infections (meropenem) may be driving carbapenem resistance. For this reason, the investigators are seeking to compare a carbapenem-sparing regimen with a carbapenem for the treatment of these infections. Formal evaluation of safety and efficacy of generic antibiotics in the treatment of infection is of immense clinical and public health importance, and no formal trial has yet been conducted to address these issues. The international collaboration between teams of clinician researchers, some of whom are leaders in their field, makes it highly likely that the outcomes of this trial will have a significant impact on clinical practice.

The investigators' hypothesis is that piperacillin/tazobactam (a carbapenem-sparing regimen) is non-inferior to meropenem (a widely used carbapenem) for the definitive treatment of bloodstream infections due to third-generation cephalosporin non-susceptible E. coli or Klebsiella species.

Description:

Escherichia coli and Klebsiella spp. are common causes of bacteraemia, and may acquire genes encoding extended-spectrum beta-lactamases (ESBLs) or AmpC beta-lactamases (1). ESBL or AmpC producers are typically resistant to third generation cephalosporins such as ceftriaxone, but susceptible to carbapenems (1). Observational studies have been performed evaluating antibiotic choices for ESBL producers (2-9). In no study has the outcome of treatment for serious infections for ESBL producers been significantly surpassed by carbapenems (2-9).

Despite the potential advantages of carbapenems for treatment of ceftriaxone non-susceptible organisms, widespread use of carbapenems may cause selection pressure leading to carbapenem-resistant organisms. This is a significant issue since carbapenem-resistant organisms are treated with "last-line" antibiotics such as colistin. Some new beta-lactam antibiotics and beta-lactamase inhibitors, which are active against ESBL, AmpC and some carbapenemase producing organisms, are in advanced clinical development (10). However, these antibiotics are likely to be expensive and may best be held in reserve for infections where there are no alternatives. Therefore, we see a need for establishing the efficacy of a generically available alternative to carbapenems for serious infections.

The susceptibility of ESBL producers and AmpC producers to piperacillin/tazobactam is less predictable than that of carbapenems. By definition, ESBLs are inhibited by beta-lactamase inhibitors such as tazobactam (1). However, E. coli or Klebsiella may produce multiple beta-lactamase types some of which are resistant to inhibition by tazobactam. Additionally, in some cases outer membrane protein loss may contribute to resistance to tazobactam. By definition, AmpC is not inhibited by beta-lactamase inhibitors such as tazobactam. However, despite these limitations, approximately 50% or more of ceftriaxone non-susceptible E. coli or Klebsiellae remain susceptible in vitro to piperacillin/tazobactam (1).

No randomised controlled trials have yet been performed comparing different treatment options for ceftriaxone resistant Enterobacteriaceae. The largest observational study with an analysis by treatment outcome was published in February 2012 by Rodriguez-Bano and colleagues (9). They performed a post-hoc analysis of six published cohorts of patients with bacteraemia due to ESBL producing E. coli. Two nonmutually exclusive cohorts (empirical therapy and definitive therapy) were constructed and analysed separately. In both cohorts, carbapenems were not superior to beta-lactam/beta-lactamase inhibitor combinations (BLBLIC). Specifically, in the definitive therapy cohort, mortality rates at 30 days were not significantly different - 9.3% for those who received a BLBLIC and 16.7% for those who received a carbapenem (p>0.20) (9).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 391
• Est. completion date: August 7, 2017
• Est. primary completion date: July 7, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Bloodstream infection with E. coli or Klebsiella spp. with proven non-susceptibility to third generation cephalosporins and susceptibility to meropenem and piperacillin-tazobactam from at least one blood culture draw. This will be determined in accordance with laboratory methods and susceptibility breakpoints defined by EUCAST standards (www. eucast.org). Bacterial identification to species level will be performed using standard laboratory methods (e.g. MALDI-TOF) and susceptibility testing (e.g. Vitek2)

• No more than 72 hours has elapsed since the first positive blood culture collection.

• Patient is aged 18 years and over

• The patient or approved proxy is able to provide informed consent.

Exclusion Criteria:

• Patient not expected to survive more than 4 days

• Patient allergic to a penicillin or a carbapenem

• Patient with significant polymicrobial bacteraemia (that is, a Gram positive skin contaminant in one set of blood cultures is not regarded as significant polymicrobial bacteraemia).

• Treatment is not with the intent to cure the infection (that is, palliative care is an exclusion).

• Pregnancy or breast-feeding.

• Use of concomitant antimicrobials in the first 4 days after enrolment with known activity against Gram-negative bacilli (except trimethoprim/sulfamethoxazole may be continued as Pneumocystis prophylaxis).

Related Conditions & MeSH terms

• Bloodstream Infections
• Infection

Intervention

Drug:
• Meropenem
Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
• Piperacillin-tazobactam combination product
Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.

Locations

Country	Name	City	State
Australia	Brisbane Private Hospital	Brisbane	Queensland
Australia	Mater Misericordiae Health Services Brisbane Ltd.	Brisbane	Queensland
Australia	St. Andrew's War Memorial Hospital	Brisbane	Queensland
Australia	Monash Health	Clayton	Victoria
Australia	Peter MacCallum Cancer Centre	East Melbourne	Victoria
Australia	Barwon Health	Geelong	Victoria
Australia	Royal Brisbane and Women's Hospital	Herston	Queensland
Australia	The Alfred Hospital	Melbourne	Victoria
Australia	Fiona Stanley Hospital	Perth
Australia	Royal Perth Hospital	Perth	Western Australia
Australia	Shellharbour Hospital (Illawarra Shoalhaven Local Health District)	Shellharbour	New South Wales
Australia	Westmead Hospital	Westmead	New South Wales
Australia	Wollongong Hospital	Wollongong	New South Wales
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland
Canada	Sunnybrook Research Institute	Toronto
Italy	Teaching Hospital - Sant'Orsola Malpighi	Bologna
Italy	Dipartimento di Scienze Biomediche e Cliniche "L. Sacco". Azienda Ospedaliera - Polo Universitario	Milan
Italy	"Sapienza" University of Rome	Rome
Italy	Catholic University Rome	Rome
Italy	Sanremo Hospital	Sanremo
Italy	Santa Maria Misericorida University Hospital	Udine
Lebanon	The American University of Beirut	Beirut
New Zealand	Middlemore Hospital	Papatoetoe
New Zealand	The North Shore Hospital	Westlake
Saudi Arabia	King Fahad Specialist Hospital	Dammam
Saudi Arabia	King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City	Riyadh
Singapore	National University Hospital	Singapore
Singapore	Tan Tock Seng Hospital	Singapore
South Africa	Groote Schuur Hospital	Cape Town
South Africa	Charlotte Maxeke Johannesberg Academic Hospital	Johannesburg
Turkey	Istanbul Medipol Üniversitesi Medipol Mega Hastaneler Kompleksi (Medipol Mega Hospitals Complex)	Istanbul

Sponsors (5)

Lead Sponsor	Collaborator
The University of Queensland	Australasian Society for Infectious Diseases, Australian Society for Antimicrobials, International Society of Chemotherapy, Queensland Clinical Trials & Biostatistics Centre

Countries where clinical trial is conducted

Australia,  Canada,  Italy,  Lebanon,  New Zealand,  Saudi Arabia,  Singapore,  South Africa,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality at 30 days	To compare the 30-day mortality post bloodstream infection of piperacillin/tazobactam and meropenem.	30 days
Secondary	Time to clinical and microbiologic resolution of infection	defined as number of days from randomisation to resolution of fever (temperature > 38.0o C) and leucocytosis (white blood cell count >12x109/L) PLUS sterilisation of blood cultures.	on or before study day 4
Secondary	Clinical and microbiologic success	defined as survival PLUS resolution of fever and leucocytosis PLUS sterilisation of blood cultures	day 4
Secondary	Microbiologic resolution of infection	defined as sterility of blood cultures collected on or before day 4	day 4
Secondary	Microbiologic relapse	defined as growth of a meropenem resistant Gram negative bacillus from any clinical specimen collected or a positive stool test (according to local lab diagnostic procedures) for C. difficile, from day 4 of study drug administration to day 30	day 30
Secondary	Superinfection with a carbapenem or piperacillin-tazobactam resistant organism or Clostridium Difficile	To compare the risk of superinfection with a carbapenem resistant organism with each regimen.	day 30